标准与循环特立帕肽及地舒单抗治疗对骨小梁评分的影响:一项随机临床试验的事后分析
70例绝经后骨质疏松女性随机接受标准方案(特立帕肽18个月后地舒单抗18个月,n=32)或循环方案(3个周期各6个月特立帕肽后序贯地舒单抗,n=32),在完成36个月随访的50例中分析骨小梁评分(TBS)。两组TBS在18和36个月均较基线有改善,但组间TBS增幅无差异;TBS类别变化组间亦无差异。作者认为循环与标准方案TBS改善相似,但可能因研究把握度不足掩盖了差异。
要点
- 两组TBS在18和36个月较基线均有改善,但组间TBS增幅无差异。
- 36个月时17例TBS类别改善、4例恶化,组间类别变化无差异。
- 作者认为循环与标准方案TBS改善相似,但可能因把握度不足掩盖差异。
核心结论
- 在36个月内,循环与标准特立帕肽及地舒单抗方案的TBS改善相似,但可能因研究把握度不足掩盖了潜在差异。
研究设计与样本
- 随机临床试验的事后分析,70例绝经后骨质疏松女性随机分为标准组(特立帕肽18个月后地舒单抗18个月,n=32)或循环组(3个周期各6个月特立帕肽后序贯地舒单抗,n=32),在完成36个月随访的50例中分析TBS。
主要发现
- 基线时两组TBS相似,平均1.24 ± 0.05,被认为部分退化。
- 标准组TBS在18个月增加1.1%(p = 0.11 vs 基线),36个月增加1.6%(p < 0.11 vs 基线)。
- 循环组TBS在18和36个月分别较基线增加2.4%和2.6%(均p < 0.05 vs 基线)。
- 18和36个月时两组TBS增幅均无组间差异。
- 36个月时共17例TBS类别改善(从退化到部分退化、部分退化到正常或退化到正常),4例恶化至更低类别,组间TBS类别变化无差异。
局限性
- 作者指出可能因研究把握度不足掩盖了组间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The osteoanabolic effects of teriparatide are maximal in the first 6 months of treatment. This secondary analysis of a randomized clinical trial investigated whether cyclic teriparatide would improve Trabecular Bone Score (TBS) more than standard dosing over 36 months. Results showed similar improvements in TBS with both teriparatide regimens. INTRODUCTION: The effects of teriparatide (TPTD) are maximal in the first 6 months when bone formation exceeds resorption to the greatest degree. Cyclic use of TPTD was proposed to try to broaden this anabolic window. Prior results from this study showed that 6-month cycles of TPTD and denosumab did not improve BMD compared to standard dosing with TPTD followed by denosumab. The goal of this study was to determine if there was any difference in trabecular bone score improvement (TBS) with cyclic vs standard therapy. METHODS: 70 postmenopausal women with osteoporosis were randomized to TPTD for 18 months followed by denosumab for 18 months (standard; n = 32) or three cycles of 6 months TPTD, each followed by denosumab (cyclic; n = 32). DXA measurements of the lumbar spine (LS) were performed every 6 months and TBS calculated at baseline, 18 and 36 months on the 50 participants who completed the 36-month final study visit. This paper is a post-hoc analysis of a prior clinical trial looking at BMD change at 36 months for cyclic vs. standard dosing. RESULTS: At baseline, TBS was similar between the 2 groups with mean level 1.24 ± 0.05, considered partially degraded. In the standard group, TBS increased by 1.1% at 18 months (p = 0.11 vs baseline) and 1.6% at 36 months (p < 0.11 vs baseline). In the cyclic group, TBS increased by 2.4% and 2.6% at 18 and 36 months from baseline, respectively (both p < 0.05 vs. baseline). However, there were no group differences in TBS increments at either 18 or 36 months. At 36 months, 17 total participants had improvement in their TBS category from either degraded to partially degraded or partially degraded to normal, or degraded to normal with 4 deteriorations to a lower category. There was no difference between groups in the TBS category change. CONCLUSION: TBS improved similarly with cyclic and standard treatment regimens of TPTD and denosumab over 36 months, however possible differences may have been masked by inadequate study power.
引用
- Dash AS, Hind K, Hans D, et al. Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trial. Osteoporos Int. 2025. PMID: 40974403. doi:10.1007/s00198-025-07696-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。